Image Analysis Group Unveils Advanced AI Histology Tool to Enhance Assessment in Clinical Research
17 September, 2024, London, UK — Image Analysis Group (IAG) proudly announces publication of the interim stage deployment and validation of our cutting-edge AI-driven histology tool, designed to revolutionize the assessment of histopathology in ulcerative colitis (UC).
This innovation is the bold step into precision medicine, at international scale, and we are delighted to congratulate our collaborators, including Takeda Pharmaceuticals, Nancy University Hospital, University of Chicago, University Hospital Zurich (USZ), St. Paul’s Hospital (Canada), the University of British Columbia, University of Basel, Sheba Medical Center (Israil), University Hospital São Joã (Porto, Portugal), Tel Aviv Medical Center as well as to acknowledge all gastroenterologists and pathologists involved.
Title: Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis
Authors: David T Rubin, MD, Olga Kubassova, PhD, Christopher R Weber, MD, Shashi Adsul, MD, Marcelo Freire, MD, Luc Biedermann, MD, Viktor H Koelzer, MD, Brian Bressler, MD, Wei Xiong, PhD, Jan H Niess, MD, Matthias S Matter, MD, Uri Kopylov, MD, Iris Barshack, MD, Chen Mayer, MD, Fernando Magro, MD, Fatima Carneiro, MD, Nitsan Maharshak, MD, Ariel Greenberg, RN, Simon Hart, MSc, Jamshid Dehmeshki, PhD, Laurent Peyrin-Biroulet, MD
Journal: IBD Journals
Link: https://academic.oup.com/ibdjournal/advance-article/doi/10.1093/ibd/izae204/7758842
Ulcerative colitis, a chronic inflammatory bowel disease, requires precise histopathological assessment.
Developed under IAG’s technical guidance using deep learning, the AI tool streamlines the assessment of Whole Slide Images (WSI) by applying the A.I. powered Nancy Index paradigm to patient data with high accuracy.
The performance of the AI tool was demonstrated across nine sites in six countries. Spearheaded by clinical experts and IAG’s President Dr. Olga Kubassova, the study showcases significant advances in precision medicine.
The global roll-out follows a successful pilot phase, establishing the tool’s potential for clinical application. The AI-driven solution will be further showcased at the United European Gastroenterology (UEG) conference in Vienna from October 12 to 15, 2024, reaffirming Takeda’s and IAG’s commitment to supporting global clinical trials with scalable solutions.
For more information about Image Analysis Group and collaboration opportunities, visit www.ia-grp.com
About Image Analysis Group (IAG)
Leading imaging Clinical Research Organization (iCRO) that combines medical and operational expertise with cutting-edge proprietary A.I. capabilities to power drug development, and to deliver the potential for companion diagnostic tool. IAG has been serving biotech and pharma clients globally since 2007, reliably supporting all aspects of phase I to III imaging trials across multiple indications. With a pioneering proven innovation strategy, we enhance the value and market potential of novel therapeutic assets, as demonstrated through successful pharmaceutical partnerships.
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin